190 related articles for article (PubMed ID: 30108159)
1. In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder.
Bidlack JM; Knapp BI; Deaver DR; Plotnikava M; Arnelle D; Wonsey AM; Fern Toh M; Pin SS; Namchuk MN
J Pharmacol Exp Ther; 2018 Nov; 367(2):267-281. PubMed ID: 30108159
[TBL] [Abstract][Full Text] [Related]
2. Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats.
Burke NN; Ferdousi M; Deaver DR; Finn DP; Roche M; Kelly JP
Neuropharmacology; 2019 Mar; 146():327-336. PubMed ID: 30553825
[TBL] [Abstract][Full Text] [Related]
3. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
[TBL] [Abstract][Full Text] [Related]
4. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat.
Smith KL; Cunningham JI; Eyerman DJ; Dean RL; Deaver DR; Sanchez C
Neuropharmacology; 2019 Mar; 146():316-326. PubMed ID: 30448421
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of opioid modulation in major depressive disorder.
Ehrich E; Turncliff R; Du Y; Leigh-Pemberton R; Fernandez E; Jones R; Fava M
Neuropsychopharmacology; 2015 May; 40(6):1448-55. PubMed ID: 25518754
[TBL] [Abstract][Full Text] [Related]
6. In vivo Characterization of the Opioid Receptor-Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations.
Tan LA; Gajipara N; Sun L; Bacolod M; Zhou Y; Namchuk M; Cunningham JI
Neuropsychiatr Dis Treat; 2022; 18():2497-2506. PubMed ID: 36345421
[TBL] [Abstract][Full Text] [Related]
7. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
8. Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
Fava M; Thase ME; Trivedi MH; Ehrich E; Martin WF; Memisoglu A; Nangia N; Stanford AD; Yu M; Pathak S
Mol Psychiatry; 2020 Jul; 25(7):1580-1591. PubMed ID: 30374191
[TBL] [Abstract][Full Text] [Related]
9. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for
Obeng S; Wilkerson JL; León F; Reeves ME; Restrepo LF; Gamez-Jimenez LR; Patel A; Pennington AE; Taylor VA; Ho NP; Braun T; Fortner JD; Crowley ML; Williamson MR; Pallares VLC; Mottinelli M; Lopera-Londoño C; McCurdy CR; McMahon LR; Hiranita T
J Pharmacol Exp Ther; 2021 Mar; 376(3):410-427. PubMed ID: 33384303
[TBL] [Abstract][Full Text] [Related]
11. A role for the mu opioid receptor in the antidepressant effects of buprenorphine.
Robinson SA; Erickson RL; Browne CA; Lucki I
Behav Brain Res; 2017 Feb; 319():96-103. PubMed ID: 27818236
[TBL] [Abstract][Full Text] [Related]
12. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
Fava M; Memisoglu A; Thase ME; Bodkin JA; Trivedi MH; de Somer M; Du Y; Leigh-Pemberton R; DiPetrillo L; Silverman B; Ehrich E
Am J Psychiatry; 2016 May; 173(5):499-508. PubMed ID: 26869247
[TBL] [Abstract][Full Text] [Related]
13. Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.
Thase ME; Stanford AD; Memisoglu A; Martin W; Claxton A; Bodkin JA; Trivedi MH; Fava M; Yu M; Pathak S
Neuropsychopharmacology; 2019 Dec; 44(13):2268-2276. PubMed ID: 31254971
[TBL] [Abstract][Full Text] [Related]
14. Mercaptoacetate induces feeding through central opioid-mediated mechanisms in rats.
Stein JA; Znamensky V; Baumer F; Rossi GC; Pasternak GW; Bodnar RJ
Brain Res; 2000 May; 864(2):240-51. PubMed ID: 10802031
[TBL] [Abstract][Full Text] [Related]
15. Ethanol and Naltrexone Have Distinct Effects on the Lateral Nano-organization of Mu and Kappa Opioid Receptors in the Plasma Membrane.
Tobin SJ; Wakefield DL; Terenius L; Vukojević V; Jovanović-Talisman T
ACS Chem Neurosci; 2019 Jan; 10(1):667-676. PubMed ID: 30418735
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
[TBL] [Abstract][Full Text] [Related]
17. Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through G
Barnett ME; Knapp BI; Bidlack JM
Mol Pharmacol; 2020 Oct; 98(4):462-474. PubMed ID: 32958572
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic Characterization of Substituted Nitazenes at
Kozell LB; Eshleman AJ; Wolfrum KM; Swanson TL; Bloom SH; Benware S; Schmachtenberg JL; Schutzer KA; Schutzer WE; Janowsky A; Abbas AI
J Pharmacol Exp Ther; 2024 Apr; 389(2):219-228. PubMed ID: 38453524
[TBL] [Abstract][Full Text] [Related]
19. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
20. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
